Quality of care in patients with gout: Why is management suboptimal and what can be done about it?

Current Rheumatology Reports

Volumn 13, Issue 2, 2011, Pages 154-159

  Edwards, N Lawrence ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Allopurinol; Compliance; Education; Gout; Quality of care

Indexed keywords

ALLOPURINOL; COLCHICINE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; URATE; URIC ACID;

ABDOMINAL CRAMP; ARTICLE; CLINICAL PROTOCOL; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MEGADOSE; GASTROINTESTINAL DISEASE; GOUT; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HUMAN; HYPERURICEMIA; LOW DRUG DOSE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHYSICIAN ATTITUDE; RECOMMENDED DRUG DOSE; TREATMENT FAILURE; URIC ACID BLOOD LEVEL;

DIAGNOSTIC ERRORS; GOUT; GOUT SUPPRESSANTS; HEALTHCARE DISPARITIES; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; POLYETHYLENE GLYCOLS; QUALITY OF HEALTH CARE; SYNOVIAL FLUID; TREATMENT FAILURE; URATE OXIDASE; URICOSURIC AGENTS;

EID: 79957460417     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-010-0154-6     Document Type: Article

References (33)

1. Edwards NL. Crystal deposition diseases. In Cecil's Textbook of Medicine. 24th Edition, 2010.
2. E Pascual F Sivera 2007 Why is gout so poorly managed? Ann Rheum Disease 66 1269 1270 10.1136/ard.2007.078469 (Pubitemid 47492466)
3. DJ McCarty JL Hollander 1961 Identification of urate crystals in gouty synovial fluid Ann Intern Med 54 452 60 13773775 1:CAS:528:DyaF3MXntFOhug%3D%3D
4. N Schlesinger DG Baker HR Schumacher Jr 1999 How well have diagnostic tests and therapies for gout been evaluated? Curr Opin Rheumatol 11 441 5 10503668 10.1097/00002281-199909000-00020 1:STN:280:DyaK1MvjtV2qsQ%3D%3D
5. W Zhang M Doherty E Pascual, et al. 2006 EULAR evidence-based recommendations for gout. Part I. Diagnosis. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Disease 65 1301 11 10.1136/ard.2006.055251 1:STN:280:DC%2BD28rkslKrtA%3D%3D (Pubitemid 44641591)
6. TR Mikuls JT Farrar WB Bilker, et al. 2005 Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricemia: results from the UK General Practice Research Database (GPRD) Rheumatology 44 1038 1042 15870145 10.1093/rheumatology/keh679 1:STN:280:DC%2BD2Mznsleruw%3D%3D (Pubitemid 41487179)
7. E Roddy W Zhang M Doherty 2007 Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations Ann Rheum Disease 66 1311 1315 10.1136/ard.2007.070755 1:CAS:528:DC%2BD2sXht1Wnu7zI (Pubitemid 47492473)
8. B Pal M Foxall T Dysart, et al. 2000 How is gout managed in primary care? A review of current practice and proposed guidelines Clin Rheumatol 19 21 25 10752494 10.1007/s100670050005 1:STN:280:DC%2BD3c3hsVWmuw%3D%3D (Pubitemid 30123236)
9. R Terkeltaub 2010 Update on gout: new therapeutic strategies and options Nat Rev Rheumatol 6 30 38 20046204 10.1038/nrrheum.2009.236 1:CAS:528: DC%2BC3cXotlSi Evidence-based strategies for using established and inexpensive drugs are defined, and recommendations for the use of novel targeted approaches are outlined in this review
10. Edwards NL. Management of Hyperuricemia. In, Arthritis and Allied Conditions 16th Edition (ed WJ Koopman) Williams and Wilkins (Baltimore), 2009.
11. NL Edwards 2008 Treatment failure gout: a moving target Arthritis Rheum 58 2587 2590 18759307 10.1002/art.23803 Established ULTs allopurinol and probenecid have historically been misunderstood and misused by physicians, leading to the belief that failures in treating gout were the fault of the medication and not of the prescribing habits
12. CDA Sarawate KK Brewer W Yang, et al. 2006 Gout medication treatment patterns and adherence to standards of care from managed care perspective Mayo Clin Proc 81 925 934 16835972 10.4065/81.7.925 (Pubitemid 43993484)
13. F Perez-Ruiz F Liote 2007 Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 57 1324 1328 17907217 10.1002/art.23007 (Pubitemid 47585481)
14. JA Singh JS Hodges JP Toscano, et al. 2007 Quality of care for gout in the U needs improvement Arthritis Rheum 57 822 829 17530682 10.1002/art.22767 (Pubitemid 46932089)
15. TR Mikuls 2007 Quality of care in gout: from measurement to improvement Clin Exp Rheumatol 256 suppl 47 S114 S119
16. TR Mikuls CH MacLean J Olivieri, et al. 2004 Quality of care indicators for gout management Arthritis Rheum 50 937 943 15022337 10.1002/art.20102 (Pubitemid 38326194)
17. T Neogi DJ Hunter CE Chaisson, et al. 2006 Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study J Rheumatol 33 104 109 16267879 (Pubitemid 43054289)
18. LR Harrold RA Yood TR Mikuls, et al. 2006 Sex differences in gout epidemiology: evaluation and treatment Ann Rheum Disease 65 1368 72 10.1136/ard.2006.051649 1:STN:280:DC%2BD28rkslKrsw%3D%3D (Pubitemid 44641592)
19. CA Sarawate PA Patel HR Schumacher, et al. 2006 Serum urate levels and gout flares: analysis from managed care data J Clin Rheumatol 12 61 5 16601538 10.1097/01.rhu.0000209882.50228.9f (Pubitemid 44309598)
20. W Zhang M Doherty T Bardin, et al. 2006 EULAR evidence based recommendations for gout. Part II. Management: Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Disease 65 1312 24 10.1136/ard.2006.055269 1:CAS:528:DC%2BD28Xht1egsLbK (Pubitemid 44620440)
21. L Stamp P Gow K Sharples, et al. 2000 The optimal use of allopurinol: an audit of allopurinol use in South Auckland Aust N Z J Med 30 567 72 11108066 1:STN:280:DC%2BD3MzgsFygsg%3D%3D
22. F Perez-Ruiz A Alonso-Ruiz M Calabozo, et al. 1998 Efficacy of allopurinol and benzbromarone for the control of hyperuricemia. A pathogenic approach to the treatment of primary chronic gout Ann Rheum Disease 57 545 549 10.1136/ard.57.9.545 1:CAS:528:DyaK1cXntFCgtr0%3D (Pubitemid 28474062)
23. K Hande R Noone W Stone 1984 Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency Am J Med 76 47 56 6691361 10.1016/0002-9343(84)90743-5 1:STN:280:DyaL2c7gtFGnuw%3D%3D (Pubitemid 14216359)
24. N Dalbeth S Kumar L Stamp, et al. 2006 Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout J Rheumatol 33 1646 1650 16783857 1:CAS:528:DC%2BD28Xpt1Okt78%3D (Pubitemid 44168841)
25. J Vazquez-Mellado E Meono Morales C Pacheo-Tena, et al. 2001 Relationship between adverse events associated with allopurinol and renal function in patients with gout Ann Rheum Disease 60 981 983 10.1136/ard.60.10.981 1:STN:280:DC%2BD3MrgvFKmsA%3D%3D (Pubitemid 32885676)
26. M Becker HJ Schumacher R Wortmann, et al. 2005 Febuxostat compared with allopurinol in patients with hyperuricemia and gout N Engl J Med 353 2450 61 16339094 10.1056/NEJMoa050373 1:CAS:528:DC%2BD2MXhtlShurvE (Pubitemid 41781828)
27. J Singh V Strand 2008 Gout is associated with more comorbidity, poorer health-related quality of life and higher health care utilization in US veterans Ann Rheum Disease 67 1310 1316 10.1136/ard.2007.081604 1:STN:280: DC%2BD1crhtlWlsw%3D%3D This population-based, health-related quality-of-life assessment in US veterans with gout showed greater health care use, functional disability, and 1-year unadjusted mortality rates compared with non-gouty veterans
28. J Li-Yu G Clayburne M Sieck A Beutler M Rull E Eisner, et al. 2001 Treatment of chronic gout: can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 28 577 80 11296962 1:CAS:528:DC%2BD3MXisVyqu78%3D (Pubitemid 32202663)
29. A Shoji H Yamanaka N Kamatani 2004 A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy Arthritis Rheum 51 321 5 15188314 10.1002/art.20405 1:CAS:528: DC%2BD2cXls1Sjtr4%3D (Pubitemid 38725128)
30. MA Becker HR Schumacher Jr RL Wortmann PA MacDonald D Eustace WA Palo, et al. 2005 Febuxostat compared with allopurinol in patients with hyperuricemia and gout N Engl J Med 353 2450 61 16339094 10.1056/NEJMoa050373 1:CAS:528:DC%2BD2MXhtlShurvE (Pubitemid 41781828)
31. F Perez-Ruiz M Calabozo MJ Fernandez-Lopez A Herrero-Beites E Ruiz-Lucea G Garcia-Erauskin, et al. 1999 Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study J Clin Rheumatol 5 49 55 19078356 10.1097/00124743-199904000-00003 1:STN:280: DC%2BD1M%2FivF2guw%3D%3D (Pubitemid 29217861)
32. F Perez-Ruiz M Calabrozo AM Herrero-Beites G Garcia-Erauskin JI Pijoan 2000 Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts Nephron 86 287 91 11096285 10.1159/000045783 1:STN:280:DC%2BD3M%2FmtV2htg%3D%3D
33. Y-P Siu KT Leung MKH Tong, et al. 2006 Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level Am J Kid Disease 47 51 59 10.1053/j.ajkd.2005.10.006 1:CAS:528: DC%2BD28Xpt1emug%3D%3D (Pubitemid 41828266)